While the DAPA-CKD trial suggests a beneficial effect of SGLT2 inhibitors in CKD of non-metabolic origin, the number of patients with Alport syndrome included on this cohort was low and therefore conclusions cannot be extrapolated for this population at this time. The gene discussed is SLC5A2; the disease is chronic kidney disease.